NIH Continues Collaboration With Palantir Technologies to Support COVID-19 Research
October 04 2021 - 6:59AM
Business Wire
Palantir Technologies Inc. (NYSE:PLTR), a leading builder of
operating systems for the modern enterprise, announced today the
National Institutes of Health's (NIH) National Center for Advancing
Translational Sciences (NCATS) has awarded Palantir a contract to
continue providing a secure cloud-based data enclave to centralize
data on COVID-19 for collaborative clinical research.
The contract to support the National COVID Cohort Collaborative
(N3C) and its data enclave is an indefinite delivery indefinite
quantity (IDIQ) contract with a total potential value of $59.5m
over two years, with an initial task order for $7.9m over the first
five months.
N3C is a partnership among more than 70 institutions to
centralize data on COVID-19 for clinical research. The N3C Data
Enclave is now one of the largest collections of COVID-19 health
records in the world, with over 8 million records from 65
institutions and counting.
Palantir’s software, designed to integrate siloed data sources
into a common environment, is ideally suited to support the N3C
Data Enclave. It has done so since the project launched in April
2020, offering a secure platform to integrate, manage, harmonize,
and analyze COVID-19 data, while providing controlled access to
internal and external collaborators.
Since the beginning of the global pandemic, N3C has accelerated
patient research and improved COVID-19 evidence, studying
everything from health inequities in treatment to risk factors for
severe and long-lasting symptoms. The large-scale data platform,
powered by Palantir software, allows researchers approved to access
the enclave to form cross-institute research teams analyzing rich
data sets, and to drive focus on populations most vulnerable to
COVID-19.
The N3C will also be used as part of the NIH RECOVER Initiative
to study post-acute sequelae from COVID-19 (PASC), or so-called
“Long COVID.”
“We are very excited to continue our work with NCATS and the
research community to support this critical resource in the fight
against COVID-19 as well as to study long COVID and potentially
other diseases that pose major public health challenges,” said
Akash Jain, Palantir USG President. “Palantir was founded to put
the most innovative software to work solving the world’s most
pressing challenges, and working to empower scientific research,
especially when it comes to helping the most vulnerable, fits
squarely within our mission.”
In addition to the contract to support the N3C, NCATS has also
extended a separate contract with Palantir for it to provide its
software to help accelerate cancer research with the National
Cancer Institute (NCI), as well as efforts to support the
President's Emergency Plan for AIDS Relief (PEPFAR). This contract,
originally for $36m over one year, has been extended for an
additional year for a total amount of $60m.
About Palantir Technologies
Palantir Technologies is a software company that builds
enterprise data platforms for use by organizations with complex and
sensitive data environments. From building safer cars and planes,
to discovering new drugs and combating terrorism, Palantir helps
customers across the public, private, and nonprofit sectors
transform the way they use their data. Additional information is
available at https://www.palantir.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These statements may relate to, but are not limited to,
Palantir’s expectations regarding the amount and the terms of the
contracts and the expected benefits of our software platforms.
Forward-looking statements are inherently subject to risks and
uncertainties, some of which cannot be predicted or quantified.
Forward-looking statements are based on information available at
the time those statements are made and were based on current
expectations as well as the beliefs and assumptions of management
as of that time with respect to future events. These statements are
subject to risks and uncertainties, many of which involve factors
or circumstances that are beyond our control. These risks and
uncertainties include our ability to meet the unique needs of our
customer; the failure of our platforms to satisfy our customer or
perform as desired; the frequency or severity of any software and
implementation errors; our platforms’ reliability; and our
customer’s ability to modify or terminate the contract. Additional
information regarding these and other risks and uncertainties is
included in the filings we make with the Securities and Exchange
Commission from time to time. Except as required by law, we do not
undertake any obligation to publicly update or revise any
forward-looking statement, whether as a result of new information,
future developments, or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211004005350/en/
Lisa Gordon media@palantir.com
Palantir Technologies (NYSE:PLTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Palantir Technologies (NYSE:PLTR)
Historical Stock Chart
From Apr 2023 to Apr 2024